Cetuximab has been demonstrated to induce an EGFR‐specific T‐cell response as well as induce antigen spreading in CRC. Cetuximab might have an immune‐enhancing effect and may favorably alter the tumor immune microenvironment. The gene discussed is EGFR; the disease is colorectal carcinoma.